(Q40476803)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15474710%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

title

Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15474710%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15474710%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

author name string

Edmunds WJ

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15474710%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

language of work or name

English

0 references

publication date

1 October 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15474710%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

number of pages

12

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15474710%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15474710%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

issue

31-32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15474710%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

page(s)

4203-4214

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15474710%20AND%20SRC:MED&resulttype=core&format=json

Meningitis in infancy in England and Wales: follow up at age 5 years

3 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.05.003

Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.05.003

Invasive pneumococcal disease in England and Wales: what is the true burden and what is the potential for prevention using 7 valent pneumococcal conjugate vaccine?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.05.003

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.05.003

Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.05.003

Impact of the pneumococcal conjugate vaccine on otitis media

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.05.003

Efficacy of a pneumococcal conjugate vaccine against acute otitis media

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.05.003

Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.05.003

Vaccination of day-care center attendees reduces carriage of Streptococcus pneumoniae among their younger siblings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.05.003

Pneumococcal conjugate vaccines: proceedings from an interactive symposium at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.05.003

The potential indirect effect of conjugate pneumococcal vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.05.003

Hospital admissions in children due to pneumococcal pneumonia in England

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.05.003

Preferences and willingness to pay for health states prevented by pneumococcal conjugate vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.05.003

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.05.003

Association of clinical signs and symptoms with bacterial findings in acute otitis media

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.05.003

Pneumococcal nasopharyngeal carriage in children following heptavalent pneumococcal conjugate vaccination in infancy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.05.003

Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.05.003

Clonal Relationships between Invasive and Carriage Streptococcus pneumoniae and Serotype‐ and Clone‐Specific Differences in Invasive Disease Potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.05.003

Acquisition and invasiveness of different serotypes of Streptococcus pneumoniae in young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.05.003

Acute otitis media in the era of effective pneumococcal conjugate vaccine: will new pathogens emerge?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.05.003

Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.05.003

Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.05.003

Carriage of pneumococci after pneumococcal vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.05.003

Vaccination against colonizing bacteria with multiple serotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.05.003

Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.05.003

Cost-utility of the cochlear implant in adults: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.05.003

The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis: a head-to-head comparison.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.05.003

Cost-effectiveness of the pneumococcal vaccine in the United States Navy and Marine Corps

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.05.003

A cost-utility analysis of second-line antibiotics in the treatment of acute otitis media in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.05.003

Epidemiology of invasive and other pneumococcal disease in children in England and Wales 1996-1998.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.05.003

Prevalence of antimicrobial-resistant pathogens in middle ear fluid: multinational study of 917 children with acute otitis media

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.05.003